Duality Biologics

Executive Summary

Duality Biologics, founded in 2019 and based in Shanghai, is a private biotechnology company specializing in the discovery and development of next-generation antibody-drug conjugates (ADCs) for oncology. Leveraging its proprietary platform, the company designs optimized ADCs with novel linkers, payloads, and antibodies to improve therapeutic windows. Although still in early stages (Phase 1), Duality aims to address key limitations of existing ADCs, such as off-target toxicity and limited efficacy. The company's approach positions it within the highly competitive ADC landscape, with potential for differentiation through its proprietary technology. As a private entity, Duality Biologics has not disclosed funding or valuation details, but its focus on ADCs—a class that has seen significant deal-making and regulatory success—suggests strong investor interest. The company's near-term progress depends on advancing its lead candidates through preclinical and early clinical studies. Key upcoming catalysts include initial clinical data readouts, regulatory milestones, and potential partnership announcements. With a focused strategy and a differentiated platform, Duality Biologics is a notable player in the Chinese ADC space, though execution risks remain typical of early-stage biotechs.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 clinical data readout for lead ADC candidate60% success
• Q4 2026IND filing for second ADC program70% success
• H2 2026Licensing or collaboration deal with major pharma40% success